[1] JANG EK, KIM WG, KIM HC, et al.Changes in the pulmonary function test after radioactive iodine treatment in patients with pulmonary metastases of differentiated thyroid cancer[J].PLoS One, 2015, 10(4):1.
[2] SHOWALTER TN, SIEGEL BA, MOLEY JF, et al.Prognostic factors in patients with well-differentiated thyroid cancer presenting with pulmonary metastases[J].Cancer Biother Radiopharm, 2008, 23(5):655. doi: 10.1089/cbr.2008.0501
[3] CHO SW, CHOI H, YEOM GJ, et al.Long-term prognosis of differentiated thyroid cancer with lung metastases in Korea and its prognostic factors[J].Thyroid, 2014, 24(2):277. doi: 10.1089/thy.2012.0654
[4] 谭建, 李亚明.再谈131Ⅰ治疗分化型甲状腺癌[ J].标记免疫分析与临床, 2014, 21(1):1.
[5] 林岩松, 李娇.2015年美国甲状腺学会《成人甲状腺结节与分化型甲状腺癌诊治指南解读:分化型甲状腺癌131Ⅰ治疗新进展[J]..中国癌症杂志, 2016, 26():1.
[6] 王任飞, 谭建, 张桂芝, 等.131Ⅰ治疗分化型甲状腺癌肺转移的疗效评价及影响因素探[J].中华核医学与分子影像杂志, 2015, 35(8):258.
[7] 袁超, 刘恒超, 胡永全, 等.131Ⅰ治疗分化型甲状腺癌术后肺转移的临床研究[J].放射免疫学杂志, 2013, 26(2):130. doi: 10.3969/j.issn.1008-9810.2013.02.002
[8] FREUDENBERG LS, JENTZEN W, MVLLER SP, et al.Disseminated iodine-avid lung metastases in differentiated thyroid cancer:a challenge to 124Ⅰ PET[J].Eur J Nucl Med Mol Imaging, 2008, 35(3):502. doi: 10.1007/s00259-007-0601-4
[9] 刘媛媛, 潘明志.131Ⅰ治疗分化型甲状腺癌肺转移疗效及影响因素的研究[J].同济大学学报(医学版), 2012, 33(3):58. doi: 10.3969/j.issn.1008-0392.2012.03.014
[10] 陆汉魁, 余永利, 罗全勇, 等.131Ⅰ治疗分化型甲状腺癌合并远处转移的疗效及影响因素[J].上海第二医科大学学报, 2005, 25(12):1263. doi: 10.3969/j.issn.1674-8115.2005.12.017
[11] SAURAV C, GARG A, BALLAL S, et al.Lung metastases from differentiated thyroid carcinoma:prognostic factors related to remission and disease-freen survival[J].Clin Endocrinol, 2015, 82(3):445. doi: 10.1111/cen.2015.82.issue-3
[12] NASCIMENTO C, BORGET I, AI GHUZLAN A, et al.Persistent disease and recurrence in differentiated Thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level[J].Endocr Relat Cancer, 2011, 18(2):R29.
[13] ROSARIO PW, XAVIER AC, CALSOLARI MR.Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and 131Ⅰ activity in patients with thyroid cancer and low risk of recurrence[J].Thyroid, 2011, 21(1):49.
[14] LONG B, YANG MD, YANG ZW, et al.Assessment of radioiodine therapy efficacy for treatment of differentiated thyroid cancer patients with pulmonary metastasis undetected by chest computed tomography[J].Oncol Lett, 2016, 11(2):965. doi: 10.3892/ol.2015.4034
[15] SONG HJ, QIU ZL, SHEN CT, et al.Pulmonary metastases in differentiated thyroid cancer:efficacy of radioiodine therapy and prognostic factors[J].Eur J Endocrinol, 2015, 173(3):399.
[16] 崔静, 刘保平, 高永举, 等.131Ⅰ显像及Tg监测131Ⅰ治疗分化型甲状腺癌肺转移灶疗效的探讨[J].中华核医学与分子影像杂志, 2012, 32(6):422. doi: 10.3760/cma.j.issn.2095-2848.2012.06.005
[17] 崔静, 革化民, 刘保平, 等.分化型甲状腺癌肺转移灶早期显影与131Ⅰ疗效关系分析[J].中华核医学与分子影像杂志, 2011, 31(4):230 doi: 10.3760/cma.j.issn.0253-9780.2011.04.006
[18] HUANG IC, CHOU FF, LIU RT, et al.Long-term outcomes of distant metastasis from differentiated thyroid carcinoma[J].Clin Endocrinol, 2012, 76(3):439. doi: 10.1111/j.1365-2265.2011.04231.x